| Subject: | FDA Issues Early Communication About An Ongoing Safety Review of Prilosec and Nexium |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 9 Aug 2007 - 11:00 am |
| The FDA has issued an early communication about the ongoing review of new safety data for the proton pump inhibitors, Prilosec (omeprazole) and Nexium (esomeprazole). The new safety data is from two small long-term clinical studies in patients with severe GERD. In both studies, patients were randomly assigned to receive treatment with a drug (either Prilosec or Nexium) or to have surgery to control their gastroesophageal reflux disease (GERD). The results from the study of... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
